Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma by unknown
BioMed Central
Journal of Experimental & Clinical 
Cancer Research
ssOpen AcceResearch
Overexpression of peroxiredoxin I and thioredoxin1 in human 
breast carcinoma
Mee-Kyung Cha, Kyung-Hoon Suh and Il-Han Kim*
Address: Department of Biochemistry, Paichai University, Daejeon 302-735, Republic of Korea
Email: Mee-Kyung Cha - mkcha@pcu.ac.kr; Kyung-Hoon Suh - khsuh@pcu.ac.kr; Il-Han Kim* - ihkim@pcu.ac.kr
* Corresponding author    
Abstract
Background: Peroxiredoxins (Prxs) are a novel group of peroxidases containing high antioxidant
efficiency. The mammalian Prx family has six distinct members (Prx I-VI) in various subcellular
locations, including peroxisomes and mitochondria, places where oxidative stress is most evident.
The function of Prx I in particular has been implicated in regulating cell proliferation, differentiation,
and apoptosis. Since thioredoxin1 (Trx1) as an electron donor is functionally associated with Prx
I, we investigated levels of expression of both Prx I and Trx1.
Methods: We investigated levels of expression of both Prx I and Trx1 in breast cancer by real-
time polymerase chain reaction (RT-PCR) and Western blot.
Results: Levels of messenger RNA (mRNA) for both Prx I and Trx1 in normal human breast tissue
were very low compared to other major human tissues, whereas their levels in breast cancer
exceeded that in other solid cancers (colon, kidney, liver, lung, ovary, prostate, and thyroid).
Among members of the Prx family (Prx I-VI) and Trx family (Trx1, Trx2), Prx I and Trx1 were
preferentially induced in breast cancer. Moreover, the expression of each was associated with
progress of breast cancer and correlated with each other. Western blot analysis of different and
paired breast tissues revealed consistent and preferential expression of Prx I and Trx1 protein in
breast cancer tissue.
Conclusion: Prx I and Trx1 are overexpressed in human breast carcinoma and the expression
levels are associated with tumor grade. The striking induction of Prx I and Trx1 in breast cancer
may enable their use as breast cancer markers.
Background
Organisms living under aerobic conditions are exposed to
reactive oxygen species (ROS) such as superoxide anion
(O2-), hydrogen peroxide (H2O2), and nitric oxide (NO),
which are generated by redox metabolism, mainly in
mitochondria. It has been demonstrated in vitro that ROS
in small amounts participate in many physiological proc-
esses such as signal transduction, cell differentiation,
apoptosis, and modulation of transcription factors [1-3].
All organisms, from prokaryotes to primates, are
equipped with different defensive systems to combat the
toxic processes of ROS. These defensive systems include
antioxidant enzymes such as superoxide dismutases, cata-
lases, glutathione peroxidases, and a new type of peroxi-
dase, the rapidly growing family of peroxiredoxins (Prxs)
[3,4].
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Sample Tissue Appearance Age/gender1 Clinical Diagnosis
BRN0 Brain Normal 26/M Normal
BRC0 Brain Tumor 40/M Astrocytoma
BEN0–4 Breast Normal 82/F. 45/F. 56/F. 64/F. 76/F Normal
BEC0 Breast Tumor 47/F Medullary Carcinoma, Well Differentiated
BEC1 Breast Tumor 40/F Invasive Lobular Carcinoma
BEC2 Breast Tumor 42/F Adenocarcinoma, Moderately Differentiated
BEC3 Breast Tumor 42/F Fibroadenoma
BEC4 Breast Tumor 50/F Infiltrative Ductal Carcinoma
CLN0 Colon Normal 60/F Normal
CLC0 Colon Tumor 48/M Adenocarcinoma, Well Differentiated
KDN0 Kidney Normal 83/F Normal
KDC0 kidney Tumor 43/F Granular Cell Carcinoma
LVN0 Liver Normal 30/M Normal
LVC0 Liver Tumor 65/M Hepatic Cellular Carcinoma
LUN0–4 Lung Normal 24/F. 26/M. 66/M. 71/M.76/F Normal
LUC0 Lung Tumor 72/M Squamous Cell Carcinoma
LUC1 Lung Tumor 33/M Squamous Cell Carcinoma, Moderately Differenciated
LUC2 Lung Tumor 51/F Adenocarcinoma, Moderately Differentiated
LUC3 Lung Tumor 58/M Squamous Cell Carcinoma, Moderately Differenciated
LUC4 Lung Tumor 61/M Adenocarcinoma
OVN0–4 Ovary Normal 74/F. 37/F. 62/F.69F. N/A/F Normal
OVC0 Ovary Tumor 51/F Cystoadenocarcinoma
OVC1 Ovary Tumor 42/F Granular Cell Tumor
OVC2 Ovary Tumor 51/F Cystoadenoma
OVC3 Ovary Tumor 57/F Leiomyosarcoma, Well Differentiated
OVC4 Ovary Tumor Adult/F Clear Cell Adenocarcinoma
BE1N Breast Adjacent Normal 70/F, same patient Normal
BE1P Breast Primary Tumor Invasive Ductal CarcinomaPage 2 of 12
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against oxidative stress, modulation of intracellular sign-
aling through H2O2 as a second messenger molecule, and
regulation of cell proliferation. Peroxiredoxins are capable
of protecting cells from ROS toxicity and regulating signal
transduction pathways that use c-Abl, caspases, nuclear
factor-kappaB (NF-κB), and activator protein-1 to influ-
ence cell growth and apoptosis. Evidence is fast growing
that oxidative stress is important not only for normal cell
physiology but also for many pathological processes such
as atherosclerosis, neurodegenerative diseases, and cancer
[5-8]. Reactive oxygen species participate in carcinogene-
sis in all stages, including initiation, promotion, and pro-
gression [5] Levels of ROS such as O2- are increased in
breast cancer [9,10]. The production of ROS accelerates
tumor induction [11]. In vitro, Prx genes I-IV are overex-
pressed when H2O2 concentration in cells is elevated [12].
Peroxiredoxin I, a cytosol form, is the most abundant and
ubiquitously distributed member of the mammalian Prx
family, and it has been identified in a large variety of
organisms. It has been suggested that Prx I regulates cell
proliferation and apoptosis by its interaction with onco-
gene products such as c-Abl. Peroxiredoxin I has been
investigated in various human cancer samples as a poten-
tial marker. The reports cited above support that Prx I may
be closely associated with cancers. Nevertheless, the con-
nection between Prx I and cancer has not yet been clearly
defined. Elevated expressions of Prx I have been observed
in several human cancers, including lung, breast, esopha-
gus, oral, and thyroid [13-15]. In oral squamous cell can-
cer, Yanagawa et al. [15] found low levels of Prx I
expression associated with larger tumor masses, lymph
node metastases, and poorly differentiated cancers. In
contrast, Karihtala et al. [16] found no correlation
between Prx I expression and clinicopathological features
in breast cancer. Instead, levels of expression of Prxs III,
IV, and V were significantly higher when breast cancers
were poorly differentiated, suggesting their relationship to
breast cancer.
There are two major Prx subfamilies. One subfamily uses
two conserved cysteines (2-Cys), and the other uses one
cysteine (1-Cys) to scavenge H2O2 and alkyl hydroperox-
ides. Four mammalian 2-Cys members (Prx I-IV) use
thioredoxin (Trx) as the electron donor for antioxidation
[17]. Thioredoxin as an antioxidant protein is induced by
various kinds of oxidative stresses [18-21]. Similar to Prxs,
Trx plays an important role in regulating cancer cell
growth, for example, by modulating the DNA binding
activity of transcription factors, including nuclear factor-
κB, p53, and glucocorticoid and estrogen receptors [22-
25]. Thioredoxin may be closely associated with cancers.
Immunohistochemical analysis using anti-Trx antibody
has shown the expression of Trx in a number of human
cancer tissues, including liver, colon, pancreas, and uter-
ine cervix [26-28]. These data indicate the possible
involvement of Trx in the process of oncogenesis.
To investigate the significance of Prx I in breast cancers, we
examined Prx I expression in 204 samples of breast cancer
tissue, as a model tissue, using quantitative methods such
BE2P Breast Primary Tumor 59/F, same patient Breast Carcinoma
BE2M Breast Metastatic Tumor Breast Tumor Metastasized to Lung
CL1N Colon Adjacent Normal 62/F. same patient Normal
CL1P Colon Primary Tumor Adenocarcinoma
CL2P Colon Primary Tumor 66/F. same patient Adenocarcinoma
CL2M Colon Metastatic Tumor Colon Tumor Metastasized to Lymph Node
LU1N Lung Adjacent Normal 46/M, same patient Normal
LU1P Lung Primary Tumor Squamous Cell Carcinoma
LU2P Lung Primary Tumor 75/M. same patient Squamous Cell Carcinoma
LU2M Lung Metastatic Tumor Lung Tumor Metastasized to Lymph Node
1The information of age & gender was placed in order (e.g., BEN0, 82/F; BEN1, 45/F; BEN2, 56/F; BEN2, 64/F; BEN3, 76/F). Zero series of sample 
(e.g., BRN0) were used in the experiment shown in Figure 7. Abbreviations: N, Normal; C, Cancer; P, Primary Cancer; M, Metastatic Cancer or 
Male; F, Female; N/A, not available; Br, Brain; BE, breast; LV, Liver; LU, Lung; OV, Ovary; CL, colon.
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Western blot, and we investigated association with cancer
grade. Since Trx1 is functionally associated with Prx I as
the electron donor, we also examined the expression of
Trx in the same tissues. The association of Trx1 with Prx I
may indicate a physiological role for Prx I in breast cancer.
Methods
Study Material for Real-Time PCR Analysis
We used Human Major 48 Tissues real-time (HMRT)
quantitative PCR arrays, Cancer Survey real-time (CSRT
96-I) quantitative PCR arrays, and Human Breast Cancer
real-time (BCRT I-V) qPCR arrays from OriGene (OriGene
Technologies, Inc, Rockville, MD, USA). Simultaneous
examination of the expression of target genes in 48 differ-
ent tissues was performed using the HMRT array, which
consisted of panels of first-strand complementary DNA
(cDNA) from human tissues selected from individuals of
different ethnicity. Expression levels of target genes in
eight different cancers (breast, colon, kidney, liver, lung,
ovary, prostate, and thyroid) were measured using the
CSRT array, consisting of 12 samples from each cancer
type with cancer stage from I to IV. Expression of target
genes in breast cancer was examined using four different
sets of arrays (BCRT I-IV) to test 192 samples and using
the CSRT 96-I array to test 12 samples. In the 204 samples,
grading was distributed as follows: stage 0 (normal), 19;
stage I, 37; stage II, 76; stage III, 60; and stage IV, 12. The
cancer tissue types consisted of ductal (n = 154), lobular
(n = 13), metastatic (n = 12), and other histological types
of cancer (n = 25), including medullary, mucinous, tubu-
lar, recurrent, and papillary. More clinicopathological
information for each patient is described in OriGene's
product sheet. TissueScan Cancer qPCR Arrays are panels
of normalized cDNA prepared from pathologist-verified
human tumor tissues. The cDNAs were prepared from
high quality cancer tissues.
Study Material for Immunological Analysis
Total membrane and soluble proteins from clinically
defined human cancer and normal tissues were obtained
from Capital Biosciences (Gaithersburg, MD, USA). The
proteins were prepared from high quality and pathologist-
verified cancer tissues The proteins from different individ-
uals and matched paired individuals (normal tissue and
primary cancers; primary and metastatic cancers) were
used for immunological analysis. The clinical and patho-
logical findings of the cancers are summarized in Table 1.
Immunological Analysis
Immunoblotting was performed according to the manu-
facturer's instructions using the Amersham ECL Western
blotting system (GE Healthcare, Chalfont St. Giles, United
Kingdom). Anti-Prx I, anti-Prx II, anti-Trx1, and anti-cop-
per/zinc (Cu/Zn) superoxide dismutase (SOD) rabbit pol-
yclonal antibodies that have cross-reactivity with the
corresponding human protein were purchased from
AbFrontier (Seoul, Korea). Samples were fractionated by
electrophoresis on a 4% to 20% gradient sodium dodecyl
sulfate (SDS) polyacrylamide gel (PAGE) (GenScript
Corp, Piscataway, NJ, USA) and transferred onto polyvi-
nylidene difluoride membranes (Millipore, Billerica, MA,
USA). The membranes were blocked and incubated with
antibody (1:1000 by volume) in phosphate-buffered
saline (PBS) containing 0.1% Tween 20 at room tempera-
ture for 2 hours. After extensive washing, the membranes
were incubated with polyclonal goat anti-rabbit IgG anti-
body (1:2000 by volume) conjugated with horseradish
peroxidase. The membranes were washed in PBS, and the
chemiluminescent substrate was added. The membranes
were stripped and stained with Coomassie Blue R-250 for
verification of the loading sample.
Table 2: Sequence of Primers for Real-Time PCR1 Amplification
Primer for Direction Primer Sequence (5' to 3')
Human Prx I Forward tttggtatcagacccgaagc
Reverse tccccatgtttgtcagtgaa
Human Prx II Forward ccagacgcttgtctgaggat
Reverse acgttgggcttaatcgtgtc
Human Prx III Forward gttgtcgcagtctcagtgga
Reverse gacgctcaaatgcttgatga
Human Prx IV Forward cagctgtgatcgatggagaa
Reverse taatccaggccaaatgggta
Human Prx V Forward ccctggatgttccaagacac
Reverse aagatggacaccagcgaatc
Human Prx IV Forward cgtgtggtgtttgtttttgg
Reverse tcttcttcagggatggttgg
Human Trx1 Forward ctgcttttcaggaagccttg
Reverse tgttggcatgcatttgactt
Human Trx2 Forward agcccggacaatatacacca
Reverse aatatccaccttggccatca
1 Abbreviations: PCR, polymerase chain reaction; Prx, peroxiredoxin; 
Trx, thioredoxin.Page 4 of 12
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Quantitative RT-PCR was performed to characterize the
expression profile of human target genes by using the
human quantitative (q) RT-PCR arrays (Origene) per the
manufacturer's instructions. Polymerase chain reaction
was performed in 96-well optical plates using the iCycler
(Bio-Rad Laboratories, Hercules, CA, USA) with primers
specific for Prx I-VI, Trx1, Trx2, β-actin, glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), and iQ SYBR Green
Supermix (Bio-Rad). The resulting fluorescence propor-
tional to the amount of amplified DNA was measured at
the end of each elongation phase at 530 nm. A standard
graph of CT (the point at which the fluorescence crosses
the threshold) values obtained from serially diluted target
genes was constructed for all reactions to ensure that they
were amplified and reported in proportion to template. CT
Expression Profiles of Peroxiredoxin I and Thioredoxin1 in 48 Major Human TissuesFigure 1
Expression Profiles of Peroxiredoxin I and Thioredoxin1 in 48 Major Human Tissues. The Human Major Tissue 
qRT-PCR array was used to determine transcript levels of Prx I (Figure 1A) and Trx1 (Figure 1B). For the human tissue array, 
tissues were selected from 48 individuals of different ethnicity. The y-axis represents the value of pg × 104 of DNA determined. 
Data were abtained using the comparative CT method with the values normalized to GAPDH levels and a standard curve. 
Details are in the "Materials and Method" section. Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; Prx I, 
peroxiredoxin I; qRT-PCR, quantitative real-time polymerase chain reaction; Trx1, thioredoxin 1.Page 5 of 12
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plate cDNA using the equation 2ΔΔCT. The ΔCT is the abun-
dance of cDNAs for transcripts of each gene normalized to
the β-actin and GAPDH at each time point. The ΔΔCT is
obtained by subtracting a calibrator value for each gene
transcript being assayed. In parallel with each cDNA sam-
ple, standard curves were generated to correlate CT values
using serial dilutions of the target gene. The quality of the
standard curve was judged from the slope and the correla-
tion coefficient. Quantification was performed by com-
paring the fluorescence of a PCR product of unknown
concentration with the fluorescence of several dilutions.
Melting curve analysis was used for product validation.
The primers for β-actin and GAPDH were supplied by Ori-
gene. Other primer sequences are summarized in Table 2.
Statistical Analysis
Continuous data were reported with mean and standard
error (S.E.M); ordinal data, with numbers and percentages.
One-way analysis of variance (ANOVA) with Dunnett multi-
ple comparison test and t test were performed using Graph-
Pad Prism version 5.00 for Windows (GraphPad Software,
San Diego, CA, USA). The summary P value is represented as
a number of an asterisk. The test for linear trend between
means and column numbers was used to investigate the lin-
ear trend of data set. Values were considered statistically sig-
nificant if P < .05. In addition, Bonferroni multiple
comparison was also performed. In this test, the value was
considered statistically significant if P < .1.
Results
Preferential Increases of Prx I and Trx1 mRNA Expression 
as the Predominant Isoforms in Human Breast Cancer 
Tissue
Transcript levels of Prx I in breast tissue were very low
(0.65 × 10-4 pg), comparable to those in muscle (0.58 ×
10-4 pg), in which the Prx I level was lowest among 48
major human tissues (Figure 1A). Thioredoxin 1, as cyto-
plasmic electron donor to Prx I, was also expressed at the
lowest level (0.24 × 10-4 pg) among 48 major human tis-
sues (Figure 1B). To address whether this low expression
was specific to Prx I, we investigated mRNA levels of all
members of the Prx family (Prx I-VI) using the same 96-
well HMRT array. Expression profiles of each gene, shown
in Figure 2, revealed that all levels of Prx were lowest in
breast tissue when compared to the level of Prx in other
tissues. The expression profiles of the Prx and Trx families
in eight solid cancers (breast, colon, kidney, liver, lung,
ovary, prostate, and thyroid) were studied using the CSRT
96-I array in which 12 samples (n = 3 for normal, n = 9 for
corresponding cancer) from different individuals were
included for each type of cancer for a total of 96 samples.
As indicated in Figure 3A, the level of Prx1 mRNA was ele-
vated in breast cancer by the highest fold (9.12 ± 1.86)
among the eight types of solid tissue cancers, and the
induction levels of Prx II-VI in breast cancer ranging from
~2- to ~4-fold) were not significantly different from those
in other types of cancers (ranging from ~1- to ~3-fold).
Figure 3B showed that Trx1 was also expressed at the high-
est level in breast cancer (6.47 ± 1.22), whereas Trx2 was
Expression Profiles of Six Isoforms in the Peroxiredoxin Family in Major Human TissuesFigure 2
Expression Profiles of Six Isoforms in the Peroxiredoxin Family in Major Human Tissues. The Human Major Tis-
sue qRT-PCR array was used to determine transcript levels of Prx I-VI. Expression profiles of 26 tissues are displayed. The pro-
files of the 40 other tissues were deleted in this figure to simplify the display. Other details are in the legend of Figure 1. 
Abbreviations: Prx, peroxiredoxin; qRT-PCR, quantitative real-time polymerase chain reaction.Page 6 of 12
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(P = 0.0067).
To examine the level of expression of Prx I and Trx1
among their families in breast cancer, we measured the
expression levels for all members of the Prx and Trx fami-
lies in breast cancer using a 48-well BCRT II array (Figure
4). In normal breast tissue, all Prx isoforms showed lower
levels of expression compared with those of malignant tis-
sues. Peroxiredoxin I and Prx II were predominant among
the Prx isoforms as seen in Figure 4A (8.11 ± 1.58 × 10-4
pg for Prx I, 10.53 ± 1.33 × 10-4 pg for Prx II). Moreover,
Prx II was expressed at the highest level in normal breast
tissue among the isoforms (1.04 ± 0.23 × 10-4 pg for Prx
I, 2.25 ± 0.34 × 10-4 pg for Prx II; P = 0.046 for Prx I vs.
Prx II) (Figure 4A). In terms of induction fold of mRNA in
breast cancer tissue, Prx I expression was highest among
the six isoforms (8.64 ± 1.40 fold) (Figure 3B). For the Trx
isoforms (Trx1 and Trx2), in both normal and malignant
tissues, the expression level of Trx1 was much higher than
that of Trx2 (Figure 4C). In Figure 4D, the higher-fold
induction of Trx1 in malignant tissue is depicted com-
pared with Trx2.
Association of Prx I and Trx1 to Breast Cancer Grade
To evaluate the association of Prx I and Trx1 with grade of
breast cancer, we measured mRNA levels in 204 samples
of normal and malignant breast tissues ranging from 0 to
IV grade by qRT-PCR and determined the induction fold
from normal (grade 0) to malignant (grade I, II, III, IV).
Expression of Prx I and Trx1 genes in breast cancer was
assessed using five different sets of qRT-PCR arrays. Induc-
tion fold data were displayed as a scatter dot plot (Figure
5A). In breast cancer, 2-fold overexpression of Prx I
occurred in 181 of 185 cases (97.8%), and 2-fold overex-
pression of Trx1 occurred in 168 of 185 cases (90.8%).
Mean ± SEM induction folds were 7.90 ± 0.45 for Prx I and
5.64 ± 0.33 for Trx1.
To examine the relationship between mRNA expression of
Prx I and Trx1 and progress of cancer, we displayed the
data as box-and-whisker plots (cancer phase versus induc-
tion fold mRNA expression) (Prx I, Figure 5B; Trx1, Figure
5C). In both Prx I and Trx1, there was a significant rela-
tionship between the induction fold and increasing cancer
phase, especially for metastatic cancer (comparison of Prx
I expression from stage I to stage IV, P = .040; Trx1, P =
.009). Stage IV (n = 12) was classified as metastatic cancer.
In addition, we divided the cancer phases into subdivi-
sions (stages I, IIA, IIB, IIIA, IIIB, IIIC, and IV) and com-
pared these by induction fold expression. As shown in
Figure 5D, induction fold was associated with subdivi-
sions of cancer stages (P = .0181 for Prx I and P = .0191
for Trx1)
Increased mRNA Levels of Peroxiredoxin and Thioredoxin Families in Eight Canc r Tissues Compared with Normal Tis-suesigur  3
Increased mRNA Levels of Peroxiredoxin and 
Thioredoxin Families in Eight Cancer Tissues Com-
pared with Normal Tissues. Cancer Survey qRT-PCR 
array was used to determine the transcript levels of Prx I-VI, 
Trx1, and Trx2 in breast, colon, kidney, liver, lung, ovary, 
prostate, and thyroid cancers. Samples in each of the eight 
cancer groups in the set of arrays consisted of three samples 
of normal tissue and nine samples of cancer tissues (cancer, 
phases I-IV) from different individuals. Data were analyzed 
using the comparative CT method with the values normalized 
to GAPDH levels. The y-axis represents the increase in the 
induction fold of the mRNA level of cancer tissue compared 
with the data from three samples of normal tissue. Error bar 
displays the range of standard error. Figure in inset is a scat-
ter plot with individual values of the induction fold for Prx I 
depicted by each dot, the mean induction fold depicted by 
the longer horizontal line, and standard error depicted by the 
error bars (shorter horizontal lines) above and below the 
mean line. Clinicopathological information for each patient 
was provided by the supplier. Abbreviations: GAPDH, glycer-
aldehyde 3-phosphate dehydrogenase; mRNA, messenger 
RNA; Prx, peroxiredoxin; qRT-PCR, quantitative real-time 
polymerase chain reaction; Trx, thioredoxin.Page 7 of 12
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To investigate an association between Prx I and Trx1 in
human breast cancer, we plotted the both induction folds
in breast cancer as x-y plot (x-axis for that of Prx I mRNA;
y-axis for that of Trx1 mRNA). Figure 6 depicts the corre-
lation between induction folds of Prx I and Trx1 genes in
breast cancer (Pearson r = 0.6875; P < .0001), indicating
an association between Prx I and Trx1 in breast cancer.
Preferential Overexpression of Prx I and Trx1 Protein in 
Human Breast Cancer Tissue
To examine the expression of Prx I and Trx1 proteins,
Western blot analysis was conducted of protein lysates
from seven cancer tissue types (brain, breast, colon, kid-
ney, liver, lung, and ovary) separated by SDS-PAGE. Both
Prx I and Trx1 proteins appeared to be elevated at the
highest level when compared with those of other tissues
(Figure 7A). Western blot analysis of the human breast
cancer samples revealed a band at approximately 40 kDa.
Western blot analysis in Figure 7B showed that the band
in the reducing gel was entirely shifted to several higher
molecular weight forms as shown in the nonreducing gel,
suggesting that the 40-kDa band represents the dimer
form of Prx I. The presence of multimeric forms of Prx I,
including the dimer and decamer forms, has been previ-
ously reported [29].
Figure 8 displays Western blots for samples of four normal
tissues and four cancer tissues from different individuals
(different from the samples used in the previous experi-
ment; see Table 1). The stronger band intensities for Prx I
and Trx1 proteins indicate overexpression in breast cancer
tissue, compared with those of lung and ovary.
A comparative Western blot analysis between the paired
sets of breast tissue (paired normal and primary cancer
from the same individual; paired primary and metastatic
cancer from the same individual) and the paired sets of
other tissues (lung and colon) revealed preferential over-
expression of Prx I and Trx1 proteins in breast cancer com-
pared with those in lung and colon cancer, and higher
protein levels of Prx I and Trx1 in metastatic breast cancer
than in primary breast cancer (Figure 9). Similarly, Prx II
protein was overexpressed in breast cancer, but the Prx II
protein level in normal tissue was significantly higher
than that of Prx I in normal tissue. These comparative pro-
tein levels in normal and malignant tissues correspond
with the levels of Prx II mRNA shown in Figure 4A.
These Western data shown in Figures 7, 8, 9 indicate that
Prx I protein was overexpressed in 7 of 8 cases (87.5%) of
breast cancer but in none of the 6 cases of normal breast
tissue. Thioredoxin1 protein was overexpressed in 6 of 8
cases (75.0%) of breast cancer.
Predominant Expressions of Peroxiredoxin I and Thioredoxin1 mRNA in Breast Cancer TissueFigure 4
Predominant Expressions of Peroxiredoxin I and Thioredoxin1 mRNA in Breast Cancer Tissue. Data in Figure 
4A and Figure 4C show the transcript levels of Prx I and Trx1, respectively. The BCRT II array (qRT-PCR) was used to deter-
mine the transcript levels of Prx I-VI, Trx1, and Trx2. Data were analyzed using the comparative CT method with the values 
normalized to β-actin level and expressed relative to controls. In parallel with each cDNA sample, standard curves were gen-
erated to correlate CT values using serial dilutions of the target gene. The y-axis represents the value of pg of DNA × 104. The 
induction fold data shown in Figure 4B and Figure 4D were obtained from the expression profiles in Figure 4A and Figure 4C, 
respectively. The BCRT II array consisted of five samples of normal breast tissue and 43 samples of breast cancer tissues from 
different individuals. Clinicopathological information for each patient was provided by the supplier. Values are reported as 
mean ± standard error. The t test was performed for levels of induction fold for Prx I versus other Prx isoforms (Figure 4B), 
and for Trx1 versus Trx2 (Figure 4D). The P values are represented by asterisks (** = P < .01, *** = P < .001). Abbreviations: 
BCRT II, Human Breast Cancer qRT-PCR Array II; mRNA, messenger RNA; Prx, peroxiredoxin; qRT-PCR, quantitative real-
time polymerase chain reaction; Trx, thioredoxin.Page 8 of 12
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To our knowledge, there has been only one previous
report suggesting overexpression of Prx I protein in
human breast cancer. Overexpression of Prx I was detected
in 21 of 24 patients (87.5%) with breast cancer, but no
significant relationship was found between overexpres-
sion of Prx I and progress in breast cancer [13]. Their find-
ing of overexpression of Prx I protein in breast cancer
tissue by Western immunoblotting agrees with our obser-
vations (7 of 8 cases, 87.5%; 0 of 6 normal, 0%). One
study has examined the association of overexpression of
Prx I protein with clinicopathological parameters in oral
cancer [15]. Low Prx I expression in oral cancer was asso-
ciated with larger tumor mass and poorly differentiated
cancer cells. In our study, all samples of breast cancer stage
IV, which belonged to metastatic breast cancers, were
found to overexpress Prx I at the highest level. Moreover,
in our study of 204 samples, Prx I expression was signifi-
cantly associated with increasing cancer progress.
We examined all six members of the Prx family in eight
human cancers (breast, colon, kidney, liver, lung, ovary,
prostate, and thyroid) and found that Prx I was preferen-
tially induced only in breast cancer, not in other cancer tis-
Peroxiredoxin I and Thioredoxin1 mRNA Levels Associated with Grade of Breast CancerFigure 5
Peroxiredoxin I and Thioredoxin1 mRNA Levels Associated with Grade of Breast Cancer. Data from the breast 
cancer groups using the Cancer Survey qPCR array (n = 9) and Breast Cancer qRT-PCR array I-V (n = 176) are displayed as a 
scatter dot plot with mean and standard error (Figure 5A). Data for induction fold for each cancer grade are represented as 
box-and-whisker plots with minimum and maximum. The t test was performed to compare induction fold between grade I and 
grade IV (Prx I, Figure 5B; Trx1, Figure 5C). The P values are represented by asterisks (** = P < .01). In addition, the Bonferroni 
test for multiple comparison was also performed. In this test, the P value was considered statistically significant if P < .1. The 
number of samples per grade and subdivided grade was distributed as follows: grade I, 37; grade II, 76 (IIA, 44; IIB, 32); grade III, 
60 (IIIA, 32; IIIB, 9; IIIC, 19); and grade IV, 12. All samples in grade IV (n = 12) represent metastatic cancer. To investigate the 
association between induction fold and cancer grade, one-way ANOVA test for linear trend was performed between mean 
induction fold and subdivided cancer grades (Figure 5D). For Prx I, slope = 0.6217, P = .02; for Trx1, slope = 0.4497, P = .02. 
For both cases, linear trends were considered statistically significant if P < .05. Clinicopathological information for each patient 
was provided by the supplier. Abbreviations: ANOVA, analysis of variance; Prx I, peroxiredoxin I; qRT-PCR, quantitative real-
time polymerase chain reaction; Trx1, thioredoxin 1.
Correlation Between Peroxiredoxin I and Thioredoxin1 mRNA Expressions in B east CancerFigure 6
Correlation Between Peroxiredoxin I and 
Thioredoxin1 mRNA Expressions in Breast Cancer. 
Data of induction folds of Prx I and Trx1 in breast cancer 
shown in Figure 5A are displayed as a scatter plot. Details are 
in the legend of Figure 5. Abbreviations: Prx I, peroxiredoxin 
I; Trx1, thioredoxin 1.Page 9 of 12
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Western Analysis of Peroxiredoxin I and Thioredoxin1 Protein Expressions in Malignant and Normal TissuesFigure 7
Western Analysis of Peroxiredoxin I and Thioredoxin1 Protein Expressions in Malignant and Normal Tissues. 
The total membrane and soluble protein lysates (15 μg) were loaded into reducing (Figure 7A and left side of Figure 7B) and 
nonreducing SDS-PAGE (right side of Figure 7B) and analyzed for protein expression. The sample information is described in 
Table 1. For example, N and C under the heading "Brain" are represented as BRN0 and BRC0 in Table 1, respectively. Figure 
7B shows oligomerization for Prx I. Abbreviations: C, cancer (malignant); D, dimer; kDa, kilodalton; M, monomer; N, normal; 
Prx I, peroxiredoxin I; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel; Tet, tetramer; Tri, trimer; Trx1, thioredoxin 1.
Western Analysis of Peroxiredoxin I and Thioredoxin1 Protein Expressions in Malignant and Normal TissuesFigure 8
Western Analysis of Peroxiredoxin I and Thioredoxin1 Protein Expressions in Malignant and Normal Tissues. 
Four samples each of normal and cancer tissue providing total membrane and soluble protein lysates (15 μg) were loaded into 
reducing SDS-PAGE (right side of Figure 8B) and analyzed for protein expression. The sets of three blots with one antibody 
(breast [BE], lung [LU], and ovary [OV]) were exposed on the same film at the same time. The sample information is described 
in Table 1. For example, N1 and C1 under the heading of "Breast (BE)" are represented as BEN1 and BEC1 in Table 1, respec-
tively. Abbreviations: C, cancer (malignant); N, normal; Prx I, peroxiredoxin I; SDS-PAGE, sodium dodecyl sulfate polyacryla-
mide gel; Trx1, thioredoxin 1.
Journal of Experimental & Clinical Cancer Research 2009, 28:93 http://www.jeccr.com/content/28/1/93sues. The isoforms Prx I and II were highly expressed in
breast cancer. The expression level of Prx II was slightly
higher than that of Prx I in breast cancer, but the induction
fold of Prx I was significantly higher than that of Prx II.
This apparent inconsistency seems to be caused by the
lower level of Prx I mRNA in normal breast tissue com-
pared with that of Prx II.
At present, few studies have been conducted on all six Prx
members in various human cancers [13,16]. In contrast to
our observations, other results have shown high protein
expression of Prxs III, IV, and V in breast cancer, but not
Prxs I, II, V, and VI. Immunoreactive protein and mRNA
levels do not necessarily correspond with each other, as
previously seen in a study of Prx V in rat tissues [30]. This
suggests that both translational and posttranslational
mechanisms probably have effects on Prx protein expres-
sion in human tissues. For example, destabilizing Prx pro-
teins by overoxidation or phosphorylation leads to
degradation, which results in reduced protein levels in
cancer tissue [31,32]. Such posttranslational modification
in cancer tissue could be one of the reasons for the dis-
crepancy between mRNA and protein levels of Prx I in
breast tissue. A more reliable approach may be to assess
the level of transcription in cancer samples. In our study,
we attempted to measure transcription.
As an electron donor, Trx is essential to cellular function
of Prx [17]. Of the two isoforms of human Trx, cytoplas-
mic Trx1 and mitochondrial Trx2, we focused on Trx1 in
breast cancer tissue because of its localization with Prx I.
As with Prx I, there are many reports that Trx1 may be
closely associated with cancers. Previous studies have
shown the expression of Trx1 in a number of human can-
cer tissues [26-28,33,34]. Estrogen receptors and p53 are
important transcription factors in the growth regulation
of cancer cells in breast cancer. Previous findings suggest
that Trx1 expression is linked to the estrogen receptor-
dependent and p53-dependent regulation of growth in
breast cancer cells [34]. This observation is consistent with
the association of Trx1 and breast cancer. In the present
study, we demonstrated that increasing Trx1 expression
was associated with progress of breast cancer, and that
Trx1 was correlated with Prx I in human breast cancer. It
is not certain that, in breast cancer, the involvement of
Trx1 reflects its ability to regulate Prx I action, but at least
in terms of magnitude of expression in the same patients,
the association of Trx1 with Prx1 supports the theory that
their functions are related to each other in breast cancer.
Conclusion
We have demonstrated here that Prx I and Trx1 are prefer-
entially overexpressed in human breast carcinoma and the
expression levels are associated with tumor grade. In addi-
tion, Prx I expression is correlated with Trx1 expression in
breast cancer. We found that mRNA levels for both Prx I
and Trx1 in normal breast tissue are extremely low com-
pared with those of other major human tissues. Based on
these observations, we suggest that Prx I and Trx1 could be
used as potential breast cancer markers.
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Western Analysis of Peroxiredoxin I, Peroxiredoxin II, Thior doxi 1, and Copper/Zinc Superoxide Dismutase Pro-tein Expression  in Paired Samples of Malignant and Distant Normal Ti ue Hom g nates of the Same P tientFigu e 9
Western Analysis of Peroxiredoxin I, Peroxiredoxin 
II, Thioredoxin1, and Copper/Zinc Superoxide Dis-
mutase Protein Expressions in Paired Samples of 
Malignant and Distant Normal Tissue Homogenates 
of the Same Patient. The total membrane and soluble 
protein lysates (15 μg) were loaded into reducing SDS-PAGE 
analyzed for protein expression. The patient information is 
described in Table 1. Cu/Zn SOD was included in this exper-
iment as a positive control. Abbreviations: Cu/Zn SOD, cop-
per/zinc superoxide dismutase; M, metastatic cancer; N, 
normal; P, primary cancer; Prx I, peroxiredoxin I; Prx II, per-
oxiredoxin II; SDS-PAGE, sodium dodecyl sulfate polyacryla-
mide gel; Trx1, thioredoxin 1.Page 11 of 12
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